-
公开(公告)号：US20170275371A1
公开(公告)日：2017-09-28
申请号：US15615032
申请日：2017-06-06
Inventor： Christopher John FRANCIS , Hua-Xin GAO , Yufeng LI , Niranjan YANAMANDRA
IPC: C07K16/28 , A61K31/7028 , C07K16/30 , A61K39/395
CPC classification number: C07K16/2878 , A61K31/7008 , A61K31/7028 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/3046 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/75 , A61K2300/00
Abstract: Disclosed herein are combinations of an OX40 modulator and a TLR4 modulator, pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering said combination, including uses in cancer.
-
公开(公告)号：US20190256599A1
公开(公告)日：2019-08-22
申请号：US16322538
申请日：2017-08-03
Inventor： Sabyasachi BHATTACHARYA , Paul M. BOJCZUK , Heather L. JACKSON , Mili MANDAL , Hong SHI , Sapna YADAVILLI , Niranjan YANAMANDRA
Abstract: The present invention provides methods for increasing expression of ICOS on an effector T cell comprising contacting said effector T cell with an anti-PD-1 antibody. The present invention also provides methods for decreasing expression of ICOS on a regulatory T cell comprising contacting said regulatory T cell with an anti-PD-1 antibody. The present invention provides methods for increasing sensitivity to an agent directed to ICOS in a human comprising administering to the human an anti-PD1 antibody. The present invention also provides methods of treating cancer in a human in need thereof comprising administering an anti-PD-1 antibody and an anti-ICOS antibody to said human, wherein the anti-PD-1 antibody increases T cell sensitivity to the ICOS antibody.
-
公开(公告)号：US20180222990A1
公开(公告)日：2018-08-09
申请号：US15749553
申请日：2016-08-03
Inventor： Axel HOOS , Niranjan YANAMANDRA
IPC: C07K16/28 , A61P35/00 , A61K39/395 , A61K45/06
CPC classification number: C07K16/2878 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/507 , A61K2039/54 , A61K2039/545 , A61P35/00 , C07K16/2818 , C07K2317/21 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/70 , C07K2317/75 , C07K2317/76
Abstract: Disclosed herein are combinations of an OX40 modulator and a CTLA-4 modulator, pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering said combination, including uses in cancer.
-
Patent Agency Ranking
公开(公告)号：US20180222989A1
公开(公告)日：2018-08-09
申请号：US15749355
申请日：2016-08-03
Inventor： Axel HOOS , Niranjan YANAMANDRA
IPC: C07K16/28 , A61P35/00 , A61K45/06 , A61K39/395
CPC classification number: C07K16/2878 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/54 , A61K2039/545 , A61P35/00 , C07K16/2818 , C07K2317/21 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/74 , C07K2317/75 , C07K2317/76
Abstract: Disclosed herein are combinations of an OX40 modulator and a PD-1 modulator, pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering said combination, including uses in cancer.
-
公开(公告)号：US20200181275A1
公开(公告)日：2020-06-11
申请号：US16620782
申请日：2018-06-08
Inventor： Christopher B. HOPSON , David J. KILIAN , Patrick A. MAYES , Sapna YADAYILLI , Niranjan YANAMANDRA
Abstract: The present invention provides methods of treating cancer in a patient in need thereof, the method comprising administering to the patient an effective amount of an agent directed to human ICOS and an effective amount of an agent directed to human OX40 sequentially. The present invention also provides an anti-ICOS antibody or antigen binding fragment thereof and an anti-OX40 antibody or antigen binding fragment thereof for sequential use in treating cancer in a human in need thereof.
-
公开(公告)号：US20190338042A1
公开(公告)日：2019-11-07
申请号：US16455957
申请日：2019-06-28
Inventor： Christopher John FRANCIS , Hua-Xin GAO , Yufeng LI , Niranjan YANAMANDRA
IPC: C07K16/28 , A61K39/395 , A61K31/7008 , A61K31/7028 , C07K16/30 , A61K45/06
Abstract: Disclosed herein are combinations of an OX40 modulator and a TLR4 modulator, pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering said combination, including uses in cancer.
-
公开(公告)号：US20190256608A1
公开(公告)日：2019-08-22
申请号：US15780331
申请日：2016-12-01
Inventor： Patrick A. MAYES , Laura M. SEESTALLER-WEHR , Lyuben TSVETKOV , Niranjan YANAMANDRA , Jingsong YANG
Abstract: Disclosed herein are combinations of an antigen binding protein that binds BCMA with a antigen binding protein that bind to an immunomodulatory agents, such as PD-1 or OX40, pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering said combinations, including uses in cancer.
-
公开(公告)号：US20190023791A1
公开(公告)日：2019-01-24
申请号：US15749141
申请日：2016-08-03
Inventor： Axel HOOS , David KAUFMAN , Elaine PINHEIRO , Herbert STRUEMPER , Niranjan YANAMANDRA
Abstract: The present invention provides methods of treating cancer in a human in need thereof comprising administering to the human: a therapeutically effective amount of a monoclonal antibody that binds to human OX40 comprising: (a) a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:1; (b) a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:2; (c) a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:3; (d) a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:7; (e) a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:8; and (f) a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:9; and a therapeutically effective amount of a monoclonal antibody that binds to human PD-1 comprising: (a) a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:54; (b) a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:55; (c) a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:56; (d) a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:57; (e) a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:58; and (f) a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:59.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.023 seconds)
